• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Esmya 5 mg Tablets
    / CTS


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    28 X 5 mg

    partial basket chart 44502

    Dosage

    The usual dosage is: one tablet of Esmya 5 mg per day, for a treatment cycle up to 3 months.
    The 3-months treatment may be repeated only once. If an additional 3-months treatment with Esmya has been recommended to you by the doctor, you should start taking it as early as possible during the second menstrual cycle after completion of the first cycle.
    You should start treatment during the first week of the menstrual cycle.
    The medicine should be taken with water. The medicine may be taken with or without food.


    Indications

    Esmya is a medicine intended for treatment of moderate to severe symptoms of uterine myomas in adult women (over 18 years old) of childbearing age, before surgery for removal of uterine myomas.
    Uterine myomas are benign tumors of the uterine muscle tissue that might cause increased menstrual bleeding, pelvic pain (abdominal discomfort) and pressure on different organs.


    Contra-Indications

    Do not use this medicine if:
    – You are sensitive (allergic) to Ulipristal acetate (the active ingredient) or any of the additional components, which the medicine contains.
    – You are pregnant or breastfeeding.
    – You suffer from a vaginal bleeding not due to uterine myomas.
    – You suffer from uterine cancer, cervical, ovarian or breast cancer.


    Manufacturer
    Laboratoire HRA Pharma
    Licence holder
    CLOSE